Delivery Order SPE2DB22D2211-SPE2DB24FNBV3
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, covers the delivery of Timolol 0.5% Gel-Solution (5ml) to support government healthcare programs. The $14,197.90 delivery order was issued by the Defense Logistics Agency (DLA) and has a January 2022 completion date. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a wide range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,871.28 firm fixed-price delivery order is for the supply of Timolol 0.5% gel-solution, a medication used to treat glaucoma. The award is not associated with a set-aside program and was issued as an individual delivery order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,309.28 firm fixed-price delivery order is for the supply of Timolol 0.5% Gel-Solution, a medication used for the treatment of eye conditions. The contract has a period of performance through January 31, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
- This is a firm fixed-price delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $16,334.63, is for the supply of Timolol 0.5% Gel-Solution 5ML to support federal healthcare programs. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,800.72 to AmerisourceBergen Drug Corp for Timolol 0.25% gel-solution in 5ml quantities. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by October 29, 2025, just one day after the award date of October 28, 2025. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- This is a delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of Timolol 0.5% Gel-Solution, a pharmaceutical product. The contract has a firm fixed price of $2,833.08 and a completion date of October 8, 2024. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor, and this delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that the company holds with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,956.17 firm fixed-price delivery order is for the supply of Timolol 0.5% Gel-Solution, a medication used to treat certain eye conditions. The award is not set aside for a specific business type. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999...
- This federal contract award, with ID SPE2DB20D3103/SPE2DB24FM4L9, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,586.04 delivery order is for the supply of Timolol 0.5% Gel-Solution, a pharmaceutical product, with a completion date of January 30, 2024. The contract is a firm-fixed-price delivery order and was awarded without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,907.10 Firm Fixed Price Delivery Order is for the supply of TIMOLOL 0.5% GEL-SOLUTION 5ML, with an ultimate completion date of October 23, 2024. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,066.05, is for the delivery of Timolol 0.25% Gel-Solution 5ML, a specialty medication used in the treatment of certain eye conditions. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on March 10, 2025. AmerisourceBergen holds a significant Indefinite...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB24FNBV3Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $3,139.23 firm fixed price delivery order is for the supply of Timolol 0.5% gel-solution, a pharmaceutical product, with a period of performance through March 28, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA with a potential value of $999,999,999.00 and a performance period through December 31, 2025. This IDC serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. The current delivery order is issued under this IDC. No set-aside designation was used for this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 3/27/24 |